ArticleACS medicinal chemistry letters2018
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
Article in ACS medicinal chemistry letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 30 citations in OpenAlex.
- DIS3L2-mediated RNA surveillance and extracellular vesicle packaging prevent innate immune activation by aberrant cellular RNAs.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Genomic and Untargeted Metabolomic Analysis of Secondary Metabolites in theJournal of agricultural and food chemistry · 2024Article
- LC-MS profiling, in vitro and in silico C-ABL kinase inhibitory approach to identify potential anticancer agents from Dalbergia sissoo leaves.Scientific reports · 2024Article
- Selenoproteins and tRNA-Sec: regulators of cancer redox homeostasis.Trends in cancer · 2023Review
- Structure and Candidate Biosynthetic Gene Cluster of a Manumycin-Type Metabolite fromJournal of natural products · 2022Review
- Analyzing the postulated inhibitory effect of Manumycin A on farnesyltransferase.Frontiers in chemistry · 2022Article
- Discovery of hydroxytyrosol as thioredoxin reductase 1 inhibitor to induce apoptosis and GExperimental and therapeutic medicine · 2021Article
- Inhibition of the Heat Shock Protein A (HSPA) Family Potentiates the Anticancer Effects of Manumycin A.Cells · 2021Article
- Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes-A Potential Alternative to Current Anti-Inflammatory Drugs?Microorganisms · 2020Article
- Peperomin E and its orally bioavailable analog induce oxidative stress-mediated apoptosis of acute myeloid leukemia progenitor cells by targeting thioredoxin reductase.Redox biology · 2019Article
- Effectors of thioredoxin reductase: Brevetoxins and manumycin-A.Comparative biochemistry and physiology. Toxicology & pharmacology : CBP · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The anticancer effect of manumycin A (Man A) has been attributed to the inhibition of farnesyl transferase (FTase), an enzyme that is responsible for post-translational modification of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.